Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial

The Lancet Psychiatry

Volumn 4, Issue 8, 2017, Pages 605-618

  Pagsberg, Anne Katrine ^a   Jeppesen, Pia ^a   Klauber, Dea Gowers ^a   Jensen, Karsten Gjessing ^a   Rudå, Ditte ^a   Stentebjerg Olesen, Marie ^b   Jantzen, Peter ^a   Rasmussen, Simone ^a   Saldeen, Eva Ann Sofie ^c   Lauritsen, Maj Britt Glenn ^a   Bilenberg, Niels ^d   Stenstrøm, Anne Dorte ^d   Nyvang, Louise ^a   Madsen, Sarah ^a   Werge, Thomas M ^a   Lange, Theis ^b,e   Gluud, Christian ^f   Skoog, Maria ^f   Winkel, Per ^f   Jepsen, Jens Richardt M ^a   Fagerlund, Birgitte ^a   Correll, Christoph U ^g,h,i   Fink Jensen, Anders ^b   more..

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Child and Adolescent Psychiatry   (Sweden)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e PEKING UNIVERSITY   (China)

^f International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^g ZUCKER HILLSIDE HOSPITAL   (United States)

^h DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

ⁱ FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; QUETIAPINE; NEUROLEPTIC AGENT;

ADOLESCENT; ADVERSE OUTCOME; AFFECTIVE PSYCHOSIS; AKATHISIA; ARTICLE; CHILD; CONTROLLED STUDY; DELUSIONAL DISORDER; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; ICD-10; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MICROCAPSULE; MULTICENTER STUDY; ORTHOSTATIC DIZZINESS; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA SPECTRUM DISORDER; SEDATION; SIDE EFFECT; SLEEP DISORDER; TREATMENT DURATION; TREMOR; WEIGHT GAIN; ADMINISTRATION AND DOSAGE; BODY WEIGHT GAIN; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DENMARK; PSYCHOLOGICAL RATING SCALE; REGRESSION ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; CHILD; DELAYED-ACTION PREPARATIONS; DENMARK; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUETIAPINE FUMARATE; REGRESSION ANALYSIS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 85020386918     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(17)30166-9     Document Type: Article

References (30)

1. Schimmelmann, BG, Schmidt, SJ, Carbon, M, Correll, CU, Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Curr Opin Psychiatry 26 (2013), 219–230.
2. Datta, SS, Kumar, A, Wright, SD, Furtado, VA, Russell, PS, Evidence base for using atypical antipsychotics for psychosis in adolescents. Schizophr Bull 40 (2014), 252–254.
3. Olfson, M, King, M, Schoenbaum, M, Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry 72 (2015), 867–874.
4. Grabb, MC, Gobburu, JV, Challenges in developing drugs for pediatric CNS disorders: a focus on psychopharmacology. Prog Neurobiol 152 (2016), 38–57.
5. Schneider, C, Corrigall, R, Hayes, D, Kyriakopoulos, M, Frangou, S, Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry 29 (2014), 1–10.
6. Masi, G, Milone, A, Veltri, S, Iuliano, R, Pfanner, C, Pisano, S, Use of quetiapine in children and adolescents. Paediatr Drugs 17 (2015), 125–140.
7. Citrome, L, The ABC's of dopamine receptor partial agonists—aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract 69 (2015), 1211–1220.
8. Brauner, JV, Johansen, LM, Roesbjerg, T, Pagsberg, AK, Off-label prescription of psychopharmacological drugs in child and adolescent psychiatry. J Clin Psychopharmacol 36 (2016), 500–507.
9. Pagsberg, AK, Jeppesen, P, Klauber, DG, et al. Quetiapine versus aripiprazole in children and adolescents with psychosis—protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial. BMC Psychiatry, 14, 2014, 199.
10. Kay, SR, Fizbein, A, Opler, LA, The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987), 262–276.
11. Arango, C, Robles, O, Parellada, M, et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry 18 (2009), 418–428.
12. Mozes, T, Ebert, T, Michal, SE, Spivak, B, Weizman, A, An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 16 (2006), 393–403.
13. Sikich, L, Frazier, JA, McClellan, J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165 (2008), 1420–1431.
14. Findling, RL, McKenna, K, Earley, WR, Stankowski, J, Pathak, S, Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 22 (2012), 327–342.
15. Stentebjerg-Olesen, M, Pagsberg, AK, Fink-Jensen, A, Correll, CU, Jeppesen, P, Clinical characteristics and predictors of outcome of schizophrenia-spectrum psychosis in children and adolescents: a systematic review. J Child Adolesc Psychopharmacol 26 (2016), 410–427.
16. Okkels, N, Vernal, DL, Jensen, SO, McGrath, JJ, Nielsen, RE, Changes in the diagnosed incidence of early onset schizophrenia over four decades. Acta Psychiatr Scand 127 (2013), 62–68.
17. Pagsberg, AK, Tarp, S, Glintborg, D, et al. Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials. BMJ Open, 4, 2014, e005708.
18. Stauffer, V, Case, M, Kollack-Walker, S, et al. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophr Res 130 (2011), 11–19.
19. Ballageer, T, Malla, A, Manchanda, R, Takhar, J, Haricharan, R, Is adolescent-onset first-episode psychosis different from adult onset?. J Am Acad Child Adolesc Psychiatry 44 (2005), 782–789.
20. Findling, RL, Robb, A, Nyilas, M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165 (2008), 1432–1441.
21. Savitz, AJ, Lane, R, Nuamah, I, Gopal, S, Hough, D, Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. J Am Acad Child Adolesc Psychiatry 54 (2015), 126–137.
22. Khanna, P, Suo, T, Komossa, K, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev, 1, 2014, CD006569.
23. Shoja, SS, Kaviani, H, Quetiapine versus aripiprazole in the management of schizophrenia. Ther Adv Psychopharmacol 5 (2015), 166–171.
24. Crespo-Facorro, B, de la Foz, Ortiz-Garcia, Mata, I, et al. Aripiprazole, ziprasidone and quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial. Schizophr Res 147 (2013), 375–382.
25. Pagsberg, AK, Tarp, S, Glintborg, D, et al. Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Adolesc Psychiatry 56 (2017), 191–202.
26. Jensen, JB, Kumra, S, Leitten, W, et al. A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders. J Child Adolesc Psychopharmacol 18 (2008), 317–326.
27. Al-Dhaher, Z, Kapoor, S, Saito, E, et al. Activating and tranquilizing effects of first-time treatment with aripiprazole, olanzapine, quetiapine, and risperidone in youth. J Child Adolesc Psychopharmacol 26 (2016), 458–470.
28. Desamericq, G, Schurhoff, F, Meary, A, et al. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur J Clin Pharmacol 70 (2014), 127–134.
29. Robinson, DG, Gallego, JA, John, M, et al. A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes. Schizophr Bull 41 (2015), 1227–1236.
30. Findling, RL, Johnson, JL, McClellan, J, et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 49 (2010), 583–594.